Efinaconazole

DB09040

small molecule approved

Deskripsi

Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.

Struktur Molekul 2D

Berat 348.398
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 29.9 hours in healthy patients.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

0 Data
Tidak ada data.

Target Protein

Lanosterol 14-alpha demethylase ERG11
Lanosterol 14-alpha demethylase ERG11

Referensi & Sumber

Artikel (PubMed)
  • PMID: 24249649
    Patel T, Dhillon S: Efinaconazole: first global approval. Drugs. 2013 Nov;73(17):1977-83. doi: 10.1007/s40265-013-0152-x.

Contoh Produk & Brand

Produk: 2 • International brands: 0
Produk
  • Jublia
    Solution • 100 mg/1mL • Topical • US • Approved
  • Jublia
    Solution • 10 % w/w • Topical • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul